Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Clinical Trials

13 clinical trials for Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma — RECRUITING · PHASE2
• ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma — RECRUITING · PHASE1
• Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma — RECRUITING · PHASE2
• Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T — RECRUITING · PHASE2
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE2
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy — RECRUITING · PHASE2
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
• Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma — WITHDRAWN · PHASE1
• CD19-Specific T Cells Post AlloSCT — TERMINATED · PHASE1

Refine this search